Morphotek Products Publications

Morphotek Products

CA125 effects on humoral immunosuppression
Kline JB, Nicolaides NC
Aging 2017

Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-y receptor engagement
Kline JB, Kennedy RP, Albone E, Chao Q, Fernando S, McDonough JM, Rybinski K, Wang W, Somers EB, Schweizer C, Grasso L, Nicolaides NC
Oncotarget 2017

Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer
O'Shannessy DJ, Bendas K, Schweizer C, Wang W, Albone E, Somers EB, Weil S, Meredith RK, Wustner J, Grasso L, Landers M, Nicolaides NC
Genomics 2017

Novel antibody probes for the characterization of endosialin
O'Shannessy DJ, Smith Jr MF, Somers EB, Jackson SM, Albone E, Tomkowicz B, Cheng X, Park Y, Milinichik A, Kline B, Fulton R, Oberoi P, Nicolaides NC
OncoTarget 2016 7:69420-69435

A randomized, double-blind, placebo-controlled, Phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse
Vergote I, Armstrong D, Scambia G, Teneriello M, Sehouli J, Schweizer C, Weil SC, Bamias A, Fujiwara K, Ochiai K, Poole C, Gorbunova V, Wang W, O’Shannessy D, Herzog TJ
J Clin Oncol. 2016 34:2271-2278

Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection
Gupta A, Hussein Z, Hassan R, Wustner J, Maltzman JD, Wallin BA
Cancer Chemother Pharmacol. 2016 77:733-43.

Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications
Lange SE, Zheleznyak A, Studer M, O'Shannessy DJ, Lapi SE, Van Tine BA
Oncotarget. 2016 7:13082-13092.

Endosialin and Associated Protein Expression in Soft Tissue Sarcomas: A Potential Target for Anti-Endosialin Therapeutic Strategies
O'Shannessy DJ, Dai H, Mitchell M, Huntsman S, Brantley S, Fenstermacher D, Reed DR
Sarcoma. 2016 2016:5213628.

Serum folate receptor alpha (FRA) as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression
Kurosaki A, Hasegawa K, Kato T, Abe K, Hanaoka T, Miyara A, O'Shannessy DJ, Somers EB, Yasuda M, Sekino T, Fujiwara K
Int J Cancer. 2016 138(8):1994-2002.

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer
Kim KH, Jelovac D, Armstrong DK, Schwartz B, Weil SC, Schweizer C, Alvarez RD
Gynecol Oncol. 2016 140:210-4.

Isolation of circulating tumor cells from multiple epithelial cancers with ApoStream® for detecting (or monitoring) the expression of folate receptor alpha
O’Shannessy DJ, Davis DW, Anderes K, Somers EB
Biomark Insights. 2016 11:7-18.

Folate receptor α expression level correlates with histologic grade in lung adenocarcinoma
Driver BR, Barrios R, Ge Y, Haque A, Tacha D, Cagle PT
Arch Pathol Lab Med. 2015 Nov 24.

Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies
Lee JH, Kim H, Yao Z, Lee SJ, Szajek LP, Grasso L, Pastan I, Paik CH
Nucl Med Biol. 2015 42:880-886.

Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature
Rybinski K, Imtiyaz HZ, Mittica B, Drozdowski B, Fulmer J, Furuuchi K, Fernando S, Henry M, Chao Q, Kline B, Albone E, Wustner J, Lin J, Nicolaides NC, Grasso L, Zhou Y
Oncotarget. 2015 6:25429-25440.

Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer
Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK
Clin Cancer Res. 2015 21:448-459.

Endosialin expression in metastatic melanoma tumor microenvironment vasculature: potential therapeutic implications
Kiyohara E, Donovan N, Takeshima L, Huang S, Wilmott JS, Scolyer RA, Jones P, Somers EB, O'Shannessy DJ, Hoon DS
Cancer Microenviron. 2015 8:111-118.

Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors
Fujisaka Y, Kurata T, Tanaka K, Kudo T, Okamoto K, Tsurutani J, Kaneda H, Okamoto I, Namiki M, Kitamura C, Nakagawa K
Invest New Drugs. 2015 33:380-388.

Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications
Vergote IB, Marth C, Coleman RL
Cancer Metastasis Rev. 2015 34:41-52.

Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging
Lindenberg L, Thomas A, Adler S, Mena E, Kurdziel K, Maltzman J, Wallin B, Hoffman K, Pastan I, Paik CH, Choyke P, Hassan R
Oncotarget. 2015 6:4496-4504.

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors
Sasaki Y, Miwa K, Yamashita K, Shimada K, Ishida H, Hasegawa K, Fujiwara K, Kodaira M, Fujiwara Y, Namiki M, Matsuda M, Takeuchi Y, Katsumata N
Invest New Drugs. 2015 33:332-340.

A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors
Diaz LA Jr, Coughlin CM, Weil SC, Fishel J, Gounder MM, Lawrence S, Azad N, O'Shannessy DJ, Grasso L, Wustner J, Ebel W, Carvajal RD
Clin Cancer Res. 2015 21:1281-1288.

Folate receptor-α (FOLR1) expression and function in triple negative tumors
Necela BM, Crozier JA, Andorfer CA, Lewis-Tuffin L, Kachergus JM, Geiger XJ, Kalari KR, Serie DJ, Sun Z, Aspita AM, O'Shannessy DJ, Maltzman JD, McCullough AE, Pockaj BA, Cunliffe HE, Ballman KV, Thompson EA, Perez EA
PLoS One. 2015 10:1-10.

Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers
O'Shannessy DJ, Somers EB, Wang LC, Wang H, Hsu R
J Ovarian Res. 2015 8:29-35.

Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy
Nicolaides NC, O'Shannessy DJ, Albone E, Grasso L
Front Oncol. 2014 4:1-14.

Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients
Christoph DC, Reyna-Asuncion B, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Gauler TC, Wohlschlaeger J, Schuler M, Eberhardt WE, Hirsch FR
Clin Lung Cancer. 2014 15:320-330.

Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma
Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA
Clin Cancer Res. 2014 20:5927-5936.

Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model
Li C, Chacko AM, Hu J, Hasegawa K, Swails J, Grasso L, El-Deiry WS, Nicolaides N, Muzykantov VR, Divgi CR, Coukos G
Cancer Biol Ther. 2014 15:443-451.

Development of 124l Immuno-PET Targeting Tumor Vascular TEM1/Endosialin
Chacko AM, Nayak M, Mikitsh JL, Hou C, Grasso L, Nicolaides NC, Muzykantov VR, Coukos G
J. Nucl. Med. 2014 55:1-8.

Folate receptor alpha, mesothelin and megakaryocyte potentiating factor as potential serum markers of chronic kidney disease
Somers EB, O'Shannessy DJ
Biomark Insights. 2014 9:29-37.

Influence of tumor microenvironment on prognosis in colorectal cancer: Tissue architecture-dependent signature of endosialin (TEM-1) and associated proteins
O'Shannessy DJ, Somers EB, Chandrasekaran LK, Nicolaides NC, Bordeau J, Gustavson MD
Oncotarget. 2014 5:3983-3995.

Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed
Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WE, Hirsch FR
J Thorac Oncol. 2013 8:19-30.

Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type
O'Shannessy DJ, Somers EB, Smale R, Fu YS
Int J Gynecol Pathol. 2013 32:258-268.

Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy
Despierre E, Lambrechts S, Leunen K, Berteloot P, Neven P, Amant F, O'Shannessy DJ, Somers EB, Vergote I
Gynecol Oncol. 2013 130:192-199.

Prognostic significance of FRA expression in epithelial cancers using AQUA(®) technology
O'Shannessy DJ, Gustavson M, Chandrasekaran LK, Dolled-Filhard M, Somers EB
Biomark Med. 2013 7:933-946.

Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer
O'Shannessy DJ, Jackson SM, Twine NC, Hoffman BE, Dezso Z, Agoulnik SI, Somers EB
Int. J. Mol. Sci. 2013 14:13687-13703.

Farletuzumab in Lung Cancer
Thomas A, Maltzman J, Hassan R
Lung Cancer. 2013 80:15-18.

Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL
Gynecol Oncol. 2013 129:452-458.

Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4
O'Shannessy DJ, Somers EB, Palmer LM, Thiel RP, Oberoi P, Heath R, Marcucci L
J Ovarian Res. 2013 6:29-45.

Interobserver agreement and assay reproducibility of folate receptor α expression in lung adenocarcinoma: a prognostic marker and potential therapeutic target
Bremer BE, Scoggin TS, Somers EB, O'Shannessy DJ, Tacha DE
Arch Pathol Lab Med. 2013 137:1747-1752.

The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity
Lin J, Spidel JL, Maddage CJ, Rybinski KA, Kennedy RP, Krauthauser CL, Park YC, Albone EF, Jacob S, Goserud MT, Martinez BP, Chao Q, Zhou Y, Nicolaides NC, Kline JB, Grasso L
Cancer Biol Ther. 2013 14:1032-1038.

Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance
O'Shannessy DJ, Yu G, Smale R, Fu YS, Singhal S, Theil RP, Somers EB, Vachani A
Oncotarget. 2012 3:414-425.

Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease
O'Shannessy DJ, Somers EB, Maltzman J, Smale R, Fu YS
SpringerPlus. 2012 1:22.

Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer
Farrell C, Schweizer C, Wustner J, Weil S, Namiki M, Nakano T, Nakai K, Phillips M
Cancer Chemother Pharmacol. 2012 70:727-734.

Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro
B.A. Kamen, A. K. Smith
Cancer Chemother Pharmacol. 2012 70:113-120.

Farletuzumab, a monoclonal antibody against folate receptor alpha (FRα), does not block folate or anti-folate binding or alter drug potency assessed in vitro
Kamen BA, Smith AK, Phillips M, Grasso L
J Clin Oncol. 2011 29:13544.

Characterization of the human folate receptor alpha via novel antibody-based probes
O'Shannessy DJ, Somers EB, Albone E, Cheng X, Park YC, Tomkowicz BE, Hamuro Y, Kohl TO, Forsyth TM, Smale R, Fu YS, Nicolaides NC
Oncotarget. 2011 2:1227-1243.

Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody
Shin IS, Lee SM, Kim HS, Yao Z, Regino C, Sato N, Cheng KT, Hassan R, Campo MF, Albone EF, Choyke PL, Pastan I, Paik CH
Nucl Med Biol. 2011 38:1119-1127.

Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study
Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Vander Els N, Phillip MD, Schweizer C, Weil SC, Larson SM, Old LJ
Clin Cancer Res 2010 16:5288-5295.

Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin B
Drozdowski B, Zhou Y, Kline B, Spidel J, Chan YY, Albone E, Turchin H, Chao Q, Henry M, Balogach J, Routhier E, Bavari S, Nicolaides NC, Sass PM, Grasso L
J Immune Based Ther Vaccines. 2010 8:9-18.

Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers
Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D
Clin Cancer Res. 2010 16:6132-6138.

Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy
Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC, Pastan I
Lung Cancer. 2010 68:455-459.

Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling
Tomkowicz B, Rybinski K, Sebeck D, Sass P, Nicolaides NC, Grasso L, Zhou Y
Cancer Biol Ther. 2010 9:908-915.

Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003
Smith-Jones PM, Pandit-Taskar N, Cao W, O'Donoghue J, Philips MD, Carrasquillo J, Konner JA, Old LJ, Larson SM
Nucl Med Biol. 2008 35:343-351.

Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin
Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L
Cancer Immun. 2007 19:7:20-30.

Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration
Tomkowicz B, Rybinski K, Foley B, Ebel W, Kline B, Routhier E, Sass P, Nicolaides NC, Grasso L, Zhou Y
Proc Natl Acad Sci U S A. 2007 104:17965-17970.

Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha
Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, Phillips MD, Nicolaides NC, Sass PM, Grasso L
Cancer Immun. 2007 9:7:6-14.